Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma
NCT03126461Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2018
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in melanoma, sponsored by UT Southwestern Medical Center. Primary endpoint: Change of tumor size from baseline to follow up at 36 weeks. Planned start Mar 2018; status: withdrawn.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03126461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126461.